<DOC>
	<DOC>NCT02118961</DOC>
	<brief_summary>This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents. The purposes of this study are as follows: - To confirm the non-inferiority of BK1301 to Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid) with respect to booster responses for anti-diphtheria toxoid (anti-D) and anti-tetanus toxoid (anti-T) antibodies - To confirm that booster responses for anti-pertussis toxoid (anti-PT) and anti-Filamentous Hemagglutinin (anti-FHA) antibodies are more than 80% of participants received BK1301</brief_summary>
	<brief_title>Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 11 or 12 years on the day of injection Received 3 or 4 doses of DTaP vaccine History of pertussis, diphtheria, tetanus History of anaphylaxis to vaccine components Serious conditions or diseases of the heart, vein, blood, respiratory, hepar, kidney, digestive system, psychiatric or nervous system Transfused or received gamma globulin within 3 months, or received highdose gamma globulin within 6 months before the day of injection</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>DTaP vaccine</keyword>
	<keyword>Adolescents</keyword>
</DOC>